Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study

As part of the NIRSEGAL study (https://www.nirsegal.es/en), we present the clinical characteristics and course of respiratory syncytial virus (RSV)-related low respiratory tract infection (LRTI) hospitalizations in infants eligible for nirsevimab administration during the 2023–2024 season. Infants e...

Descripción completa

Detalles Bibliográficos
Autores: Manzanares, Ángela, Pardo Seco, Jacobo José, Rivero Calle, Irene, Dacosta Urbieta, Ana Isabel, Mallah, Narmeen, Rodríguez-Tenreiro Sánchez, Carmen, Salas Ellacuriaga, Antonio, Martinón Torres, Federico
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad de Santiago de Compostela (USC)
Repositorio:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Idioma:inglés
OAI Identifier:oai:minerva.usc.gal:10347/42474
Acceso en línea:https://hdl.handle.net/10347/42474
Access Level:acceso abierto
Palabra clave:Respiratory syncytial virus (RSV)
Low respiratory tract infection (LRTI)
Nirsevimab
Breakthrough cases
Immunization
Infants
id ES_6e913abfe5d6cd3fdb4e725551a0b997
oai_identifier_str oai:minerva.usc.gal:10347/42474
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
title Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
spellingShingle Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
Manzanares, Ángela
Respiratory syncytial virus (RSV)
Low respiratory tract infection (LRTI)
Nirsevimab
Breakthrough cases
Immunization
Infants
title_short Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
title_full Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
title_fullStr Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
title_full_unstemmed Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
title_sort Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study
dc.creator.none.fl_str_mv Manzanares, Ángela
Pardo Seco, Jacobo José
Rivero Calle, Irene
Dacosta Urbieta, Ana Isabel
Mallah, Narmeen
Rodríguez-Tenreiro Sánchez, Carmen
Salas Ellacuriaga, Antonio
Martinón Torres, Federico
author Manzanares, Ángela
author_facet Manzanares, Ángela
Pardo Seco, Jacobo José
Rivero Calle, Irene
Dacosta Urbieta, Ana Isabel
Mallah, Narmeen
Rodríguez-Tenreiro Sánchez, Carmen
Salas Ellacuriaga, Antonio
Martinón Torres, Federico
author_role author
author2 Pardo Seco, Jacobo José
Rivero Calle, Irene
Dacosta Urbieta, Ana Isabel
Mallah, Narmeen
Rodríguez-Tenreiro Sánchez, Carmen
Salas Ellacuriaga, Antonio
Martinón Torres, Federico
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade de Santiago de Compostela. Departamento de Ciencias Forenses, Anatomía Patolóxica, Xinecoloxía e Obstetricia, e Pediatría
Universidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina
Universidade de Santiago de Compostela. Instituto de Ciencias Forenses "Luís Concheiro" (INCIFOR)
Universidade de Santiago de Compostela. Instituto de Psicoloxía (IPsiUS)
dc.subject.none.fl_str_mv Respiratory syncytial virus (RSV)
Low respiratory tract infection (LRTI)
Nirsevimab
Breakthrough cases
Immunization
Infants
topic Respiratory syncytial virus (RSV)
Low respiratory tract infection (LRTI)
Nirsevimab
Breakthrough cases
Immunization
Infants
description As part of the NIRSEGAL study (https://www.nirsegal.es/en), we present the clinical characteristics and course of respiratory syncytial virus (RSV)-related low respiratory tract infection (LRTI) hospitalizations in infants eligible for nirsevimab administration during the 2023–2024 season. Infants eligible for nirsevimab immunization (born between 1 April, 2023, and 30 March, 2024) who were hospitalized due to RSV-related LRTI between September 25, 2023, and April 15, 2024, in a hospital from the Galician Public Health system were included. Clinical and demographic characteristics of RSV-related LRTI hospitalizations were analyzed, with comparisons made between breakthrough cases (those immunized with nirsevimab) and non-breakthrough cases. During the study period, 69 RSV-related LRTI hospitalizations were recorded, with a median hospital stay of 4 (interquartile range (IQR) 3–6) days; 65.2% (N=45) were breakthrough cases. The median age was 2.7 (IQR 1.5–5.2) months, and more than half of them (N=39, 56.5%) were male. The incidence of cases was parallel to the RSV epidemic curve, suggesting no waning of nirsevimab efcacy. Of the total hospitalizations, 16 infants (23.2%) had a high-risk condition, 44 (63.8%) needed oxygen support, 15 (21.7%) were admitted to the intensive care unit (ICU), and 11 (15.9%) received non-invasive mechanical ventilation (NIMV). No statistically signifcant diferences were observed in these characteristics when comparing breakthrough and non-breakthrough cases. Conclusion: In the nirsevimab era, a substantial proportion of children who were hospitalized for RSV-related LRTI needed oxygen support, NIMV, and ICU admission. Clinical characteristics, timing, and outcomes were comparable between breakthrough and non-breakthrough cases. Trial registration: The NIRSE-GAL study protocol was registered on ClinicalTrials.gov (NCT06180993).
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-05-02
2025
2025-05-02
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10347/42474
url https://hdl.handle.net/10347/42474
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI24%2F00757
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PI22%2F00161 TrINeo: Aproximación ‘ómica’ al entrenamiento de la inmunidad innata del recién nacido a través de la vacunación de la madre
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) DTS19%2F00049 DIAVIR: DESARROLLO Y VALIDACION CLINICA DE UNA HERRAMIENTA MOLECULAR PARA EL DIAGNOSTICO DE ENFERMEDADES VIRALES EN SANGRE Y SALIVA BASADO EN LA DETECCION DE BIOMARCADORES TRANSCRIPTOMICOS
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F01039 RESVI-OMICS: HACIA UNA MEDICINA PERSONALIZADA EN LA INFECCION POR EL VIRUS RESPIRATORIO SINCITIAL A TRAVES DEL USO DE UNA APROXIMACION ‘-OMICA’
Ministerio de Economía y Competitividad http://dx.doi.org/10.13039/501100003329 Not available PI16-01569 ReSVinext: Estudio integrado y traslacional de la infección por Virus Respiratorio Sincitial
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F01090 ABORDAJE INTERACTOMICO TRASLACIONAL DE LA INFECCION POR ENTEROVIRUS (PROJECTO ENTEROGEN)
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023 PI22%00406 Transcriptómica, inmunogenómica y epigenómica de la protección frente al COVID-19 natural, vacunal e inducida por híbridos (estudio OMI-COVI-VAC)
European Commission http://dx.doi.org/10.13039/501100000780 Seventh Framework Programme 279185
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname:Universidad de Santiago de Compostela (USC)
instname_str Universidad de Santiago de Compostela (USC)
reponame_str Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
collection Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410433352335360
spelling Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL studyManzanares, ÁngelaPardo Seco, Jacobo JoséRivero Calle, IreneDacosta Urbieta, Ana IsabelMallah, NarmeenRodríguez-Tenreiro Sánchez, CarmenSalas Ellacuriaga, AntonioMartinón Torres, FedericoRespiratory syncytial virus (RSV)Low respiratory tract infection (LRTI)NirsevimabBreakthrough casesImmunizationInfantsAs part of the NIRSEGAL study (https://www.nirsegal.es/en), we present the clinical characteristics and course of respiratory syncytial virus (RSV)-related low respiratory tract infection (LRTI) hospitalizations in infants eligible for nirsevimab administration during the 2023–2024 season. Infants eligible for nirsevimab immunization (born between 1 April, 2023, and 30 March, 2024) who were hospitalized due to RSV-related LRTI between September 25, 2023, and April 15, 2024, in a hospital from the Galician Public Health system were included. Clinical and demographic characteristics of RSV-related LRTI hospitalizations were analyzed, with comparisons made between breakthrough cases (those immunized with nirsevimab) and non-breakthrough cases. During the study period, 69 RSV-related LRTI hospitalizations were recorded, with a median hospital stay of 4 (interquartile range (IQR) 3–6) days; 65.2% (N=45) were breakthrough cases. The median age was 2.7 (IQR 1.5–5.2) months, and more than half of them (N=39, 56.5%) were male. The incidence of cases was parallel to the RSV epidemic curve, suggesting no waning of nirsevimab efcacy. Of the total hospitalizations, 16 infants (23.2%) had a high-risk condition, 44 (63.8%) needed oxygen support, 15 (21.7%) were admitted to the intensive care unit (ICU), and 11 (15.9%) received non-invasive mechanical ventilation (NIMV). No statistically signifcant diferences were observed in these characteristics when comparing breakthrough and non-breakthrough cases. Conclusion: In the nirsevimab era, a substantial proportion of children who were hospitalized for RSV-related LRTI needed oxygen support, NIMV, and ICU admission. Clinical characteristics, timing, and outcomes were comparable between breakthrough and non-breakthrough cases. Trial registration: The NIRSE-GAL study protocol was registered on ClinicalTrials.gov (NCT06180993).SpringerUniversidade de Santiago de Compostela. Departamento de Ciencias Forenses, Anatomía Patolóxica, Xinecoloxía e Obstetricia, e PediatríaUniversidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e MedicinaUniversidade de Santiago de Compostela. Instituto de Ciencias Forenses "Luís Concheiro" (INCIFOR)Universidade de Santiago de Compostela. Instituto de Psicoloxía (IPsiUS)20252025-05-0220252025-05-02journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10347/42474reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostelainstname:Universidad de Santiago de Compostela (USC)InglésengInstituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI24%2F00757Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PI22%2F00161 TrINeo: Aproximación ‘ómica’ al entrenamiento de la inmunidad innata del recién nacido a través de la vacunación de la madreInstituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) DTS19%2F00049 DIAVIR: DESARROLLO Y VALIDACION CLINICA DE UNA HERRAMIENTA MOLECULAR PARA EL DIAGNOSTICO DE ENFERMEDADES VIRALES EN SANGRE Y SALIVA BASADO EN LA DETECCION DE BIOMARCADORES TRANSCRIPTOMICOSInstituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F01039 RESVI-OMICS: HACIA UNA MEDICINA PERSONALIZADA EN LA INFECCION POR EL VIRUS RESPIRATORIO SINCITIAL A TRAVES DEL USO DE UNA APROXIMACION ‘-OMICA’Ministerio de Economía y Competitividad http://dx.doi.org/10.13039/501100003329 Not available PI16-01569 ReSVinext: Estudio integrado y traslacional de la infección por Virus Respiratorio SincitialInstituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F01090 ABORDAJE INTERACTOMICO TRASLACIONAL DE LA INFECCION POR ENTEROVIRUS (PROJECTO ENTEROGEN)Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023 PI22%00406 Transcriptómica, inmunogenómica y epigenómica de la protección frente al COVID-19 natural, vacunal e inducida por híbridos (estudio OMI-COVI-VAC)European Commission http://dx.doi.org/10.13039/501100000780 Seventh Framework Programme 279185open accesshttp://purl.org/coar/access_right/c_abf2© The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:minerva.usc.gal:10347/424742026-06-15T12:47:27Z
score 15,812455

Similares en LA Referencia